W. Albrecht

811 total citations
34 papers, 579 citations indexed

About

W. Albrecht is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, W. Albrecht has authored 34 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Surgery, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in W. Albrecht's work include Prostate Cancer Treatment and Research (9 papers), Testicular diseases and treatments (7 papers) and Sexual Differentiation and Disorders (7 papers). W. Albrecht is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Testicular diseases and treatments (7 papers) and Sexual Differentiation and Disorders (7 papers). W. Albrecht collaborates with scholars based in Austria, Germany and United Kingdom. W. Albrecht's co-authors include W. Höltl, J. Pont, Gerhard Postner, F Sellner, Michael Marberger, Peter Albers, Gabriella Cohn‐Cedermark, Karim Fizazi, Ferrán Algaba and A. Horwich and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and British Journal of Cancer.

In The Last Decade

W. Albrecht

30 papers receiving 547 citations

Peers

W. Albrecht
Hiroaki Itatani Japan
J Dvořáček Czechia
David R. Herbold United States
M Lendon United Kingdom
A. Fishman Israel
I Richmond United Kingdom
Oded Kessler Israel
Mete Güngör Türkiye
Murat Dede Türkiye
D. Dalela India
Hiroaki Itatani Japan
W. Albrecht
Citations per year, relative to W. Albrecht W. Albrecht (= 1×) peers Hiroaki Itatani

Countries citing papers authored by W. Albrecht

Since Specialization
Citations

This map shows the geographic impact of W. Albrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Albrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Albrecht more than expected).

Fields of papers citing papers by W. Albrecht

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Albrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Albrecht. The network helps show where W. Albrecht may publish in the future.

Co-authorship network of co-authors of W. Albrecht

This figure shows the co-authorship network connecting the top 25 collaborators of W. Albrecht. A scholar is included among the top collaborators of W. Albrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Albrecht. W. Albrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albers, Peter, W. Albrecht, Ferrán Algaba, et al.. (2012). Guía clínica sobre el cáncer de testículo de la EAU: actualización de 2011. Actas Urológicas Españolas. 36(3). 127–145. 58 indexed citations
2.
Albers, Peter, W. Albrecht, Ferrán Algaba, et al.. (2010). Guía clínica sobre el cáncer de testículo. 2 indexed citations
3.
4.
Collette, Laurence, Urs E. Studer, Peter Whelan, et al.. (2006). WHICH PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT DO NOT NEED IMMEDIATE TREATMENT IN EORTC TRIAL 30891?. European Urology Supplements. 5(2). 202–202. 3 indexed citations
5.
Elandt, Katarzyna, Peter Horak, W. Albrecht, et al.. (2005). A prospective, open-label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first-line chemotherapy in patients with androgen-independent prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 4678–4678. 1 indexed citations
6.
Albrecht, W., Hendrik Van Poppel, Simon Horenblas, et al.. (2004). Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. British Journal of Cancer. 90(1). 100–105. 29 indexed citations
7.
Poppel, Hendrik Van, P. Rigatti, W. Albrecht, et al.. (2004). 280 Results of the randomized trial comparing radical and partial nephrectomy for small kidney neoplasms eortc protocol 30904. European Urology Supplements. 3(2). 72–72. 2 indexed citations
8.
Collette, Laurence, S.D. Fosså, G.O.N. Oosterhof, et al.. (2001). Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patients. European Journal of Cancer. 37. S218–S218. 4 indexed citations
9.
Heidenreich, Axel, W. Höltl, W. Albrecht, J. Pont, & U. Engelmann. (1997). Testis‐preserving surgery in bilateral testicular germ cell tumours. British Journal of Urology. 79(2). 253–257. 48 indexed citations
10.
Pont, J., et al.. (1996). Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.. Journal of Clinical Oncology. 14(2). 441–448. 148 indexed citations
11.
Laufer, Stefan, et al.. (1995). Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.. PubMed. 45(1). 27–32. 25 indexed citations
12.
Albrecht, W., et al.. (1995). 77 DRUG MONITORING OF MIZORIBINE IN RENAL TRANSPLANT PATIENTS RECEIVING AN IMMUNOSUPPRESSIVE TRIPLE THERAPY. Therapeutic Drug Monitoring. 17(4). 402–402. 1 indexed citations
13.
Montie, James E., M. Pavone‐Macaluso, Hiroshi Tazaki, et al.. (1995). What are the risks of cystectomy and the advances in perioperative care?. PubMed. 2 Suppl 2. 89–104. 4 indexed citations
14.
Marberger, Michael, et al.. (1994). Management of Ureteric Stones. European Urology. 25(4). 265–272. 58 indexed citations
15.
16.
Marberger, Michael, J. Hofbauer, Christian Türk, & W. Albrecht. (1992). Management of ureteric calculi (minimally invasive therapy of ureteric stones).. PubMed. 112(9). 729–34. 1 indexed citations
17.
Albrecht, W., et al.. (1991). Lord's Procedure—the Best Operation for Hydrocele?. British Journal of Urology. 68(2). 187–189. 14 indexed citations
18.
Hoeltl, Wolfgang, et al.. (1991). How Effective is Topical Alpha‐2b Interferon in Preventing Recurrence of Superficial Bladder Cancer?. British Journal of Urology. 68(5). 495–498. 16 indexed citations
19.
Flamm, J, Andreas Bucher, W. Höltl, & W. Albrecht. (1990). Recurrent Superficial Transitional Cell Carcinoma of the Bladder: Adjuvant Topical Chemotherapy Versus Immunotherapy. A Prospective Randomized Trial. The Journal of Urology. 144(2 Part 1). 260–263. 36 indexed citations
20.
Albrecht, W.. (1961). Konversionssymptom und Organneurose – eine Relation. Psychotherapy and Psychosomatics. 9(4). 281–294.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroaki Itatani Breakdown of academic impact, for papers by J Dvořáček Breakdown of academic impact, for papers by David R. Herbold Breakdown of academic impact, for papers by M Lendon Breakdown of academic impact, for papers by A. Fishman Breakdown of academic impact, for papers by I Richmond Breakdown of academic impact, for papers by Oded Kessler Breakdown of academic impact, for papers by Mete Güngör Breakdown of academic impact, for papers by Murat Dede Breakdown of academic impact, for papers by D. Dalela
Rankless by CCL
2026